Publisher
Springer Science and Business Media LLC
Reference83 articles.
1. Grand T, Ren S, Thokala P, Oudin Åström D, Regnier S, Hall J. Issues, challenges and opportunities for economic evaluation of orphan drugs: an umbrella review protocol. 2023. The University of Sheffield’s research data repository. 2023. https://doi.org/10.15131/shef.data.23390060.v1.
2. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA. Rare disease terminology and definitions: a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906–14. https://doi.org/10.1016/j.jval.2015.05.008.
3. The European Parliament. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 2000. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000R0141&from=EN. Accessed 20 Oct 2022.
4. Federal Food, Drug and Cosmetic Act. Orphan Drug Act. In: Senate and house of representatives of the United States of America in Congress, editor. 97th Congress: Public Law 97–114; 1983.
5. Thomas S, Caplan A. The orphan drug act revisited. JAMA. 2019;321(9):833–4. https://doi.org/10.1001/jama.2019.0290.